Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Anti-EGFR-immunoliposomes loaded with doxorubicin (C225-ILs-dox) are given intravenously in
patients with relapsed or refractory high-grade gliomas.
The pharmacokinetics of C225-ILs-dox in peripheral blood (PB), cerebro-spinal fluid (CSF) and
resected tumour tissue will be assessed.